Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Declines By 22.4%

Mustang Bio, Inc. (NASDAQ:MBIO) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 91,700 shares, a decrease of 22.4% from the February 13th total of 118,200 shares. Approximately 6.4% of the company’s shares are short sold. Based on an average trading volume of 310,600 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Mustang Bio stock. Geode Capital Management LLC lifted its stake in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 284,437 shares of the company’s stock after acquiring an additional 38,951 shares during the period. Geode Capital Management LLC owned 29.63% of Mustang Bio worth $50,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.95% of the company’s stock.

Mustang Bio Stock Up 0.7 %

Shares of MBIO stock traded up $0.01 during trading hours on Tuesday, hitting $1.43. 28,190 shares of the company were exchanged, compared to its average volume of 243,495. The firm has a market cap of $1.37 million, a PE ratio of -0.02 and a beta of 1.82. Mustang Bio has a 1 year low of $1.35 and a 1 year high of $67.00. The firm has a fifty day moving average of $4.04 and a 200 day moving average of $8.79.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.